ARMP Armata Pharmaceuticals, Inc.
Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 921114 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-135.9%
TTM EPS YoY-151.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-127.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets306.1%
Debt / equity—
Current ratio0.12x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.24x
Accruals ratio-96.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $6.83M | $7.59M | $6.11M | $6.07M | $5.82M | $6.39M | $5.43M | $8.45M |
| SG&A expense | $3.72M | $5.24M | $3.46M | $3.43M | $3.11M | $2.62M | $3.25M | $3.32M |
| Operating income | -$7.38M | -$10.31M | -$8.79M | -$13.82M | -$7.78M | -$6.84M | -$8.19M | -$10.54M |
| Income tax | $0 | $0 | $0 | — | $0 | $0 | $0 | — |
| Net income | $54.86M | $74.14M | -$115.35M | -$124.30M | -$26.68M | -$16.30M | -$6.53M | $2.60M |
| EBITDA | -$6.78M | -$9.81M | -$8.33M | -$13.40M | -$7.38M | -$6.54M | -$7.81M | -$10.16M |
| EPS (basic) | 1.15 | 2.02 | -3.16 | — | -0.74 | -0.45 | -0.18 | — |
| EPS (diluted) | -0.24 | -0.27 | -3.16 | — | -0.74 | -0.45 | -0.20 | — |
| Weighted avg. shares (diluted) | 62.68M | 62.04M | 36.53M | — | 36.23M | 36.19M | 59.48M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $18.32M | $23.95M | $4.75M | $8.69M | $14.76M | $4.33M | $11.69M | $14.77M |
| Current assets | $22.60M | $27.16M | $5.95M | $10.67M | $16.93M | $7.52M | $13.17M | $11.31M |
| PP&E, net | $10.80M | $11.23M | $11.78M | $12.19M | $12.56M | $12.66M | $12.88M | $13.24M |
| Goodwill | $3.49M | $3.49M | $3.49M | $3.49M | $3.49M | $3.49M | $3.49M | $3.49M |
| Intangibles | $10.26M | $10.26M | $10.26M | $10.26M | $10.26M | $10.26M | $10.26M | $10.26M |
| Total assets | $84.48M | $89.95M | $69.80M | $76.88M | $89.52M | $80.79M | $87.25M | $86.44M |
| Current liabilities | $186.78M | $250.20M | $9.23M | $8.95M | $139.95M | $120.08M | $110.54M | $48.25M |
| Total liabilities | $258.61M | $321.12M | $381.39M | $295.48M | $185.10M | $150.29M | $141.03M | $134.46M |
| Shareholders' equity | -$174.13M | -$231.17M | -$311.59M | -$218.60M | -$95.59M | -$69.50M | -$53.78M | -$48.02M |
| Shares outstanding | 37.19M | 37.15M | — | 36.43M | 36.64M | 36.19M | 36.19M | 36.18M |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.52M | -$8.67M | -$5.78M | -$6.67M | -$4.30M | -$7.21M | -$7.58M | -$7.93M |
| Capital expenditure | $91,000 | $17,000 | $63,000 | $52,000 | $242,000 | $149,000 | $99,000 | -$77,000 |
| Free cash flow | -$5.61M | -$8.68M | -$5.84M | -$6.73M | -$4.54M | -$7.36M | -$7.68M | -$7.85M |
| Investing cash flow | -$91,000 | -$17,000 | -$63,000 | -$52,000 | -$242,000 | -$149,000 | -$99,000 | $77,000 |
| Financing cash flow | -$28,000 | $27.88M | $641,000 | $658,000 | $14.97M | $0 | $9.99M | $0 |
| Depreciation & amortization | $600,000 | $500,000 | $457,000 | $418,000 | $400,000 | $300,000 | $377,000 | $380,000 |
| Stock-based compensation | $2.22M | $3.39M | $1.07M | $632,000 | $622,000 | $575,000 | $781,000 | $354,000 |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.